nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—KIT—myenteric nerve plexus—rectum cancer	0.0309	0.0666	CbGeAlD
Regorafenib—PDGFRA—penis—rectum cancer	0.0219	0.0473	CbGeAlD
Regorafenib—RET—autonomic nervous system—rectum cancer	0.0217	0.0468	CbGeAlD
Regorafenib—FRK—renal system—rectum cancer	0.00895	0.0193	CbGeAlD
Regorafenib—DDR2—smooth muscle tissue—rectum cancer	0.00834	0.018	CbGeAlD
Regorafenib—DDR2—mammalian vulva—rectum cancer	0.00751	0.0162	CbGeAlD
Regorafenib—FRK—female reproductive system—rectum cancer	0.00717	0.0155	CbGeAlD
Regorafenib—EPHX2—seminal vesicle—rectum cancer	0.00673	0.0145	CbGeAlD
Regorafenib—DDR2—female reproductive system—rectum cancer	0.00643	0.0139	CbGeAlD
Regorafenib—MAPK11—female reproductive system—rectum cancer	0.0061	0.0132	CbGeAlD
Regorafenib—DDR2—vagina—rectum cancer	0.00582	0.0126	CbGeAlD
Regorafenib—EPHX2—urethra—rectum cancer	0.00533	0.0115	CbGeAlD
Regorafenib—FLT4—epithelium—rectum cancer	0.00527	0.0114	CbGeAlD
Regorafenib—EPHX2—mammalian vulva—rectum cancer	0.00507	0.011	CbGeAlD
Regorafenib—EPHA2—seminal vesicle—rectum cancer	0.005	0.0108	CbGeAlD
Regorafenib—UGT1A9—renal system—rectum cancer	0.00496	0.0107	CbGeAlD
Regorafenib—FGFR1—urethra—rectum cancer	0.00474	0.0102	CbGeAlD
Regorafenib—FLT1—seminal vesicle—rectum cancer	0.00472	0.0102	CbGeAlD
Regorafenib—RAF1—seminal vesicle—rectum cancer	0.00469	0.0101	CbGeAlD
Regorafenib—RET—epithelium—rectum cancer	0.00465	0.0101	CbGeAlD
Regorafenib—FGFR1—mammalian vulva—rectum cancer	0.00451	0.00974	CbGeAlD
Regorafenib—FGFR2—epithelium—rectum cancer	0.00442	0.00955	CbGeAlD
Regorafenib—EPHA2—epithelium—rectum cancer	0.00435	0.00939	CbGeAlD
Regorafenib—RET—renal system—rectum cancer	0.00432	0.00933	CbGeAlD
Regorafenib—FGFR2—smooth muscle tissue—rectum cancer	0.00426	0.0092	CbGeAlD
Regorafenib—TEK—epithelium—rectum cancer	0.00424	0.00916	CbGeAlD
Regorafenib—BRAF—vagina—rectum cancer	0.00411	0.00888	CbGeAlD
Regorafenib—FGFR2—renal system—rectum cancer	0.0041	0.00886	CbGeAlD
Regorafenib—FLT1—epithelium—rectum cancer	0.0041	0.00885	CbGeAlD
Regorafenib—TEK—smooth muscle tissue—rectum cancer	0.00409	0.00882	CbGeAlD
Regorafenib—RAF1—epithelium—rectum cancer	0.00408	0.0088	CbGeAlD
Regorafenib—KDR—seminal vesicle—rectum cancer	0.00399	0.00862	CbGeAlD
Regorafenib—EPHA2—urethra—rectum cancer	0.00396	0.00855	CbGeAlD
Regorafenib—FLT1—smooth muscle tissue—rectum cancer	0.00395	0.00853	CbGeAlD
Regorafenib—TEK—renal system—rectum cancer	0.00393	0.00849	CbGeAlD
Regorafenib—EPHX2—vagina—rectum cancer	0.00393	0.00848	CbGeAlD
Regorafenib—RAF1—smooth muscle tissue—rectum cancer	0.00393	0.00848	CbGeAlD
Regorafenib—FLT4—female reproductive system—rectum cancer	0.00392	0.00846	CbGeAlD
Regorafenib—TEK—urethra—rectum cancer	0.00386	0.00834	CbGeAlD
Regorafenib—FLT1—renal system—rectum cancer	0.0038	0.00821	CbGeAlD
Regorafenib—RAF1—renal system—rectum cancer	0.00378	0.00816	CbGeAlD
Regorafenib—EPHA2—mammalian vulva—rectum cancer	0.00377	0.00814	CbGeAlD
Regorafenib—DDR2—lymph node—rectum cancer	0.00376	0.00812	CbGeAlD
Regorafenib—FLT1—urethra—rectum cancer	0.00374	0.00807	CbGeAlD
Regorafenib—RAF1—urethra—rectum cancer	0.00371	0.00802	CbGeAlD
Regorafenib—PDGFRA—smooth muscle tissue—rectum cancer	0.0037	0.00799	CbGeAlD
Regorafenib—MAPK11—lymph node—rectum cancer	0.00357	0.0077	CbGeAlD
Regorafenib—PDGFRA—renal system—rectum cancer	0.00356	0.0077	CbGeAlD
Regorafenib—FLT1—mammalian vulva—rectum cancer	0.00356	0.00768	CbGeAlD
Regorafenib—RAF1—mammalian vulva—rectum cancer	0.00354	0.00764	CbGeAlD
Regorafenib—KIT—seminal vesicle—rectum cancer	0.00354	0.00763	CbGeAlD
Regorafenib—FGFR1—vagina—rectum cancer	0.00349	0.00755	CbGeAlD
Regorafenib—KDR—epithelium—rectum cancer	0.00347	0.00748	CbGeAlD
Regorafenib—PDGFRB—seminal vesicle—rectum cancer	0.00345	0.00746	CbGeAlD
Regorafenib—UGT1A1—renal system—rectum cancer	0.0034	0.00734	CbGeAlD
Regorafenib—KDR—smooth muscle tissue—rectum cancer	0.00334	0.00721	CbGeAlD
Regorafenib—FGFR2—female reproductive system—rectum cancer	0.00329	0.0071	CbGeAlD
Regorafenib—EPHA2—female reproductive system—rectum cancer	0.00323	0.00697	CbGeAlD
Regorafenib—KDR—renal system—rectum cancer	0.00321	0.00694	CbGeAlD
Regorafenib—KDR—urethra—rectum cancer	0.00316	0.00682	CbGeAlD
Regorafenib—TEK—female reproductive system—rectum cancer	0.00315	0.0068	CbGeAlD
Regorafenib—ABL1—seminal vesicle—rectum cancer	0.00308	0.00665	CbGeAlD
Regorafenib—KIT—epithelium—rectum cancer	0.00307	0.00663	CbGeAlD
Regorafenib—FLT1—female reproductive system—rectum cancer	0.00305	0.00658	CbGeAlD
Regorafenib—RAF1—female reproductive system—rectum cancer	0.00303	0.00654	CbGeAlD
Regorafenib—KDR—mammalian vulva—rectum cancer	0.00301	0.00649	CbGeAlD
Regorafenib—PDGFRB—epithelium—rectum cancer	0.003	0.00648	CbGeAlD
Regorafenib—KIT—smooth muscle tissue—rectum cancer	0.00296	0.00639	CbGeAlD
Regorafenib—EPHA2—vagina—rectum cancer	0.00292	0.00631	CbGeAlD
Regorafenib—PDGFRB—smooth muscle tissue—rectum cancer	0.00289	0.00624	CbGeAlD
Regorafenib—PDGFRA—female reproductive system—rectum cancer	0.00285	0.00616	CbGeAlD
Regorafenib—KIT—renal system—rectum cancer	0.00285	0.00615	CbGeAlD
Regorafenib—KIT—urethra—rectum cancer	0.0028	0.00604	CbGeAlD
Regorafenib—PDGFRB—renal system—rectum cancer	0.00278	0.00601	CbGeAlD
Regorafenib—FLT1—vagina—rectum cancer	0.00275	0.00595	CbGeAlD
Regorafenib—RAF1—vagina—rectum cancer	0.00274	0.00591	CbGeAlD
Regorafenib—PDGFRB—urethra—rectum cancer	0.00273	0.0059	CbGeAlD
Regorafenib—KIT—mammalian vulva—rectum cancer	0.00266	0.00575	CbGeAlD
Regorafenib—BRAF—lymph node—rectum cancer	0.00266	0.00574	CbGeAlD
Regorafenib—PDGFRB—mammalian vulva—rectum cancer	0.0026	0.00562	CbGeAlD
Regorafenib—PDGFRA—vagina—rectum cancer	0.00258	0.00557	CbGeAlD
Regorafenib—ABL1—smooth muscle tissue—rectum cancer	0.00258	0.00556	CbGeAlD
Regorafenib—KDR—female reproductive system—rectum cancer	0.00257	0.00556	CbGeAlD
Regorafenib—EPHX2—lymph node—rectum cancer	0.00254	0.00549	CbGeAlD
Regorafenib—ABL1—renal system—rectum cancer	0.00248	0.00536	CbGeAlD
Regorafenib—ABL1—urethra—rectum cancer	0.00244	0.00526	CbGeAlD
Regorafenib—KDR—vagina—rectum cancer	0.00233	0.00503	CbGeAlD
Regorafenib—ABL1—mammalian vulva—rectum cancer	0.00232	0.00501	CbGeAlD
Regorafenib—FLT4—lymph node—rectum cancer	0.00229	0.00495	CbGeAlD
Regorafenib—KIT—female reproductive system—rectum cancer	0.00228	0.00493	CbGeAlD
Regorafenib—FGFR1—lymph node—rectum cancer	0.00226	0.00488	CbGeAlD
Regorafenib—PDGFRB—female reproductive system—rectum cancer	0.00223	0.00481	CbGeAlD
Regorafenib—KIT—vagina—rectum cancer	0.00206	0.00446	CbGeAlD
Regorafenib—RET—lymph node—rectum cancer	0.00202	0.00437	CbGeAlD
Regorafenib—PDGFRB—vagina—rectum cancer	0.00202	0.00435	CbGeAlD
Regorafenib—ABL1—female reproductive system—rectum cancer	0.00199	0.00429	CbGeAlD
Regorafenib—ABCG2—seminal vesicle—rectum cancer	0.00194	0.00419	CbGeAlD
Regorafenib—EPHA2—lymph node—rectum cancer	0.00189	0.00408	CbGeAlD
Regorafenib—TEK—lymph node—rectum cancer	0.00184	0.00398	CbGeAlD
Regorafenib—ABL1—vagina—rectum cancer	0.0018	0.00388	CbGeAlD
Regorafenib—FLT1—lymph node—rectum cancer	0.00178	0.00385	CbGeAlD
Regorafenib—RAF1—lymph node—rectum cancer	0.00177	0.00383	CbGeAlD
Regorafenib—PDGFRA—lymph node—rectum cancer	0.00167	0.00361	CbGeAlD
Regorafenib—CYP2C8—renal system—rectum cancer	0.00161	0.00347	CbGeAlD
Regorafenib—ABCG2—urethra—rectum cancer	0.00154	0.00332	CbGeAlD
Regorafenib—KDR—lymph node—rectum cancer	0.00151	0.00325	CbGeAlD
Regorafenib—ABCG2—mammalian vulva—rectum cancer	0.00146	0.00316	CbGeAlD
Regorafenib—CYP2B6—renal system—rectum cancer	0.00144	0.00312	CbGeAlD
Regorafenib—CYP2C19—vagina—rectum cancer	0.00133	0.00288	CbGeAlD
Regorafenib—KIT—lymph node—rectum cancer	0.00133	0.00288	CbGeAlD
Regorafenib—PDGFRB—lymph node—rectum cancer	0.0013	0.00282	CbGeAlD
Regorafenib—CYP2C8—female reproductive system—rectum cancer	0.00129	0.00278	CbGeAlD
Regorafenib—CYP2C8—vagina—rectum cancer	0.00116	0.00252	CbGeAlD
Regorafenib—ABL1—lymph node—rectum cancer	0.00116	0.00251	CbGeAlD
Regorafenib—CYP2B6—female reproductive system—rectum cancer	0.00116	0.0025	CbGeAlD
Regorafenib—CYP2C9—female reproductive system—rectum cancer	0.00114	0.00247	CbGeAlD
Regorafenib—ABCG2—vagina—rectum cancer	0.00113	0.00245	CbGeAlD
Regorafenib—CYP3A4—renal system—rectum cancer	0.00109	0.00235	CbGeAlD
Regorafenib—CYP2B6—vagina—rectum cancer	0.00104	0.00226	CbGeAlD
Regorafenib—ABCB1—seminal vesicle—rectum cancer	0.000957	0.00207	CbGeAlD
Regorafenib—CYP3A4—female reproductive system—rectum cancer	0.000872	0.00188	CbGeAlD
Regorafenib—ABCB1—epithelium—rectum cancer	0.000831	0.0018	CbGeAlD
Regorafenib—ABCB1—renal system—rectum cancer	0.000771	0.00167	CbGeAlD
Regorafenib—ABCB1—urethra—rectum cancer	0.000758	0.00164	CbGeAlD
Regorafenib—ABCG2—lymph node—rectum cancer	0.000733	0.00158	CbGeAlD
Regorafenib—ABCB1—mammalian vulva—rectum cancer	0.000721	0.00156	CbGeAlD
Regorafenib—ABCB1—female reproductive system—rectum cancer	0.000618	0.00133	CbGeAlD
Regorafenib—ABCB1—vagina—rectum cancer	0.000559	0.00121	CbGeAlD
Regorafenib—ABCB1—lymph node—rectum cancer	0.000361	0.00078	CbGeAlD
Regorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.00019	0.000354	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR—KRAS—rectum cancer	0.00019	0.000353	CbGpPWpGaD
Regorafenib—KIT—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.00019	0.000353	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by NGF—NRAS—rectum cancer	0.000189	0.000352	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by NGF—NRAS—rectum cancer	0.000189	0.000351	CbGpPWpGaD
Regorafenib—BRAF—Signaling by NGF—KRAS—rectum cancer	0.000188	0.000351	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.000188	0.00035	CbGpPWpGaD
Regorafenib—FGFR1—B Cell Activation—HRAS—rectum cancer	0.000188	0.00035	CbGpPWpGaD
Regorafenib—PDGFRA—B Cell Activation—HRAS—rectum cancer	0.000187	0.000349	CbGpPWpGaD
Regorafenib—RAF1—Signaling by PDGF—KRAS—rectum cancer	0.000187	0.000348	CbGpPWpGaD
Regorafenib—RAF1—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.000187	0.000348	CbGpPWpGaD
Regorafenib—RAF1—Signaling by ERBB4—HRAS—rectum cancer	0.000184	0.000342	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by FGFR in disease—HRAS—rectum cancer	0.000182	0.00034	CbGpPWpGaD
Regorafenib—PDGFRB—DAP12 interactions—HRAS—rectum cancer	0.000182	0.00034	CbGpPWpGaD
Regorafenib—PDGFRB—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000182	0.00034	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by EGFR—HRAS—rectum cancer	0.000181	0.000337	CbGpPWpGaD
Regorafenib—MAPK11—Cellular responses to stress—TP53—rectum cancer	0.00018	0.000336	CbGpPWpGaD
Regorafenib—RAF1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.00018	0.000335	CbGpPWpGaD
Regorafenib—FGFR1—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.00018	0.000335	CbGpPWpGaD
Regorafenib—PDGFRA—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000179	0.000334	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000179	0.000334	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by PDGF—HRAS—rectum cancer	0.000178	0.000332	CbGpPWpGaD
Regorafenib—RAF1—MAPK Signaling Pathway—TP53—rectum cancer	0.000177	0.00033	CbGpPWpGaD
Regorafenib—RAF1—Insulin Signaling—HRAS—rectum cancer	0.000176	0.000328	CbGpPWpGaD
Regorafenib—RAF1—Downstream signal transduction—HRAS—rectum cancer	0.000175	0.000327	CbGpPWpGaD
Regorafenib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000175	0.000326	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by NGF—KRAS—rectum cancer	0.000175	0.000325	CbGpPWpGaD
Regorafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—rectum cancer	0.000175	0.000325	CbGpPWpGaD
Regorafenib—RAF1—Signaling by FGFR—HRAS—rectum cancer	0.000175	0.000325	CbGpPWpGaD
Regorafenib—RAF1—Signaling by ERBB2—HRAS—rectum cancer	0.000174	0.000323	CbGpPWpGaD
Regorafenib—RAF1—DAP12 signaling—HRAS—rectum cancer	0.000173	0.000322	CbGpPWpGaD
Regorafenib—PDGFRB—Focal Adhesion—HRAS—rectum cancer	0.000172	0.000321	CbGpPWpGaD
Regorafenib—EPHA2—Developmental Biology—HRAS—rectum cancer	0.000172	0.000321	CbGpPWpGaD
Regorafenib—KIT—Signaling by NGF—KRAS—rectum cancer	0.000171	0.000319	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—NRAS—rectum cancer	0.000171	0.000319	CbGpPWpGaD
Regorafenib—KDR—Axon guidance—HRAS—rectum cancer	0.00017	0.000317	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by NGF—NRAS—rectum cancer	0.00017	0.000316	CbGpPWpGaD
Regorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.000169	0.000316	CbGpPWpGaD
Regorafenib—PDGFRB—B Cell Activation—HRAS—rectum cancer	0.000169	0.000314	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—NRAS—rectum cancer	0.000166	0.000309	CbGpPWpGaD
Regorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	0.000164	0.000305	CbGpPWpGaD
Regorafenib—BRAF—Neuronal System—HRAS—rectum cancer	0.000163	0.000304	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by NGF—KRAS—rectum cancer	0.000163	0.000303	CbGpPWpGaD
Regorafenib—RAF1—Signaling by FGFR in disease—HRAS—rectum cancer	0.000163	0.000303	CbGpPWpGaD
Regorafenib—RAF1—DAP12 interactions—HRAS—rectum cancer	0.000163	0.000303	CbGpPWpGaD
Regorafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000163	0.000303	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by NGF—KRAS—rectum cancer	0.000162	0.000302	CbGpPWpGaD
Regorafenib—MAPK11—Signaling by NGF—HRAS—rectum cancer	0.000162	0.000301	CbGpPWpGaD
Regorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000162	0.000301	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR—HRAS—rectum cancer	0.000161	0.0003	CbGpPWpGaD
Regorafenib—BRAF—Signaling by NGF—HRAS—rectum cancer	0.00016	0.000298	CbGpPWpGaD
Regorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.00016	0.000298	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.00016	0.000297	CbGpPWpGaD
Regorafenib—RAF1—Signaling by PDGF—HRAS—rectum cancer	0.000159	0.000296	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000154	0.000287	CbGpPWpGaD
Regorafenib—RAF1—Focal Adhesion—HRAS—rectum cancer	0.000154	0.000286	CbGpPWpGaD
Regorafenib—RAF1—Signaling by NGF—NRAS—rectum cancer	0.000151	0.000282	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—NRAS—rectum cancer	0.00015	0.000279	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by NGF—HRAS—rectum cancer	0.000148	0.000276	CbGpPWpGaD
Regorafenib—RAF1—Transmission across Chemical Synapses—HRAS—rectum cancer	0.000147	0.000275	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—KRAS—rectum cancer	0.000147	0.000274	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by NGF—KRAS—rectum cancer	0.000146	0.000272	CbGpPWpGaD
Regorafenib—KIT—Signaling by NGF—HRAS—rectum cancer	0.000146	0.000271	CbGpPWpGaD
Regorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000144	0.000268	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—KRAS—rectum cancer	0.000143	0.000266	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—NRAS—rectum cancer	0.000143	0.000266	CbGpPWpGaD
Regorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	0.000139	0.000259	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by NGF—HRAS—rectum cancer	0.000138	0.000258	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by NGF—HRAS—rectum cancer	0.000138	0.000257	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—NRAS—rectum cancer	0.000137	0.000255	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000133	0.000247	CbGpPWpGaD
Regorafenib—RAF1—Signaling by NGF—KRAS—rectum cancer	0.00013	0.000243	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—KRAS—rectum cancer	0.000129	0.00024	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—NRAS—rectum cancer	0.000126	0.000235	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—HRAS—rectum cancer	0.000125	0.000233	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by NGF—HRAS—rectum cancer	0.000124	0.000231	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—KRAS—rectum cancer	0.000123	0.000229	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—NRAS—rectum cancer	0.000122	0.000227	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—HRAS—rectum cancer	0.000121	0.000226	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—KRAS—rectum cancer	0.000118	0.00022	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—NRAS—rectum cancer	0.000116	0.000215	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—NRAS—rectum cancer	0.000114	0.000212	CbGpPWpGaD
Regorafenib—RAF1—Neuronal System—HRAS—rectum cancer	0.000113	0.00021	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000113	0.00021	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—NRAS—rectum cancer	0.000111	0.000207	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—NRAS—rectum cancer	0.000111	0.000207	CbGpPWpGaD
Regorafenib—RAF1—Signaling by NGF—HRAS—rectum cancer	0.000111	0.000206	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—HRAS—rectum cancer	0.00011	0.000204	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—NRAS—rectum cancer	0.000109	0.000203	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—KRAS—rectum cancer	0.000108	0.000202	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—NRAS—rectum cancer	0.000108	0.000201	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—NRAS—rectum cancer	0.000108	0.0002	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—NRAS—rectum cancer	0.000107	0.000199	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—KRAS—rectum cancer	0.000105	0.000196	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—NRAS—rectum cancer	0.000105	0.000195	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—HRAS—rectum cancer	0.000104	0.000194	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—NRAS—rectum cancer	0.000104	0.000193	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—NRAS—rectum cancer	0.000103	0.000192	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—HRAS—rectum cancer	0.0001	0.000187	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—KRAS—rectum cancer	9.96e-05	0.000185	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—KRAS—rectum cancer	9.78e-05	0.000182	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—NRAS—rectum cancer	9.78e-05	0.000182	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—NRAS—rectum cancer	9.69e-05	0.00018	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—NRAS—rectum cancer	9.59e-05	0.000179	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—KRAS—rectum cancer	9.57e-05	0.000178	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—KRAS—rectum cancer	9.56e-05	0.000178	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—NRAS—rectum cancer	9.44e-05	0.000176	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—KRAS—rectum cancer	9.39e-05	0.000175	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—NRAS—rectum cancer	9.31e-05	0.000173	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—KRAS—rectum cancer	9.28e-05	0.000173	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—KRAS—rectum cancer	9.26e-05	0.000172	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—TYMS—rectum cancer	9.22e-05	0.000172	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—TYMS—rectum cancer	9.22e-05	0.000172	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—HRAS—rectum cancer	9.22e-05	0.000172	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—KRAS—rectum cancer	9.2e-05	0.000171	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—KRAS—rectum cancer	9.03e-05	0.000168	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—HRAS—rectum cancer	8.93e-05	0.000166	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—KRAS—rectum cancer	8.91e-05	0.000166	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—KRAS—rectum cancer	8.89e-05	0.000166	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—NRAS—rectum cancer	8.64e-05	0.000161	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—rectum cancer	8.5e-05	0.000158	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	8.49e-05	0.000158	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—HRAS—rectum cancer	8.46e-05	0.000158	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—KRAS—rectum cancer	8.42e-05	0.000157	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—KRAS—rectum cancer	8.34e-05	0.000155	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—HRAS—rectum cancer	8.31e-05	0.000155	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—NRAS—rectum cancer	8.29e-05	0.000154	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—NRAS—rectum cancer	8.29e-05	0.000154	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—KRAS—rectum cancer	8.26e-05	0.000154	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—HRAS—rectum cancer	8.13e-05	0.000151	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HRAS—rectum cancer	8.13e-05	0.000151	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—KRAS—rectum cancer	8.13e-05	0.000151	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—rectum cancer	8.02e-05	0.000149	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—KRAS—rectum cancer	8.01e-05	0.000149	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HRAS—rectum cancer	7.98e-05	0.000149	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—HRAS—rectum cancer	7.89e-05	0.000147	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—HRAS—rectum cancer	7.87e-05	0.000147	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—TYMS—rectum cancer	7.83e-05	0.000146	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—HRAS—rectum cancer	7.82e-05	0.000146	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—HRAS—rectum cancer	7.67e-05	0.000143	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HRAS—rectum cancer	7.58e-05	0.000141	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HRAS—rectum cancer	7.56e-05	0.000141	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	7.55e-05	0.000141	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—KRAS—rectum cancer	7.43e-05	0.000138	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—NRAS—rectum cancer	7.34e-05	0.000137	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—rectum cancer	7.34e-05	0.000137	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—HRAS—rectum cancer	7.15e-05	0.000133	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—KRAS—rectum cancer	7.14e-05	0.000133	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—KRAS—rectum cancer	7.14e-05	0.000133	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—HRAS—rectum cancer	7.09e-05	0.000132	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—HRAS—rectum cancer	7.02e-05	0.000131	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HRAS—rectum cancer	6.91e-05	0.000129	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HRAS—rectum cancer	6.81e-05	0.000127	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—NRAS—rectum cancer	6.74e-05	0.000125	CbGpPWpGaD
Regorafenib—BRAF—Disease—NRAS—rectum cancer	6.71e-05	0.000125	CbGpPWpGaD
Regorafenib—KIT—Immune System—NRAS—rectum cancer	6.62e-05	0.000123	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—rectum cancer	6.34e-05	0.000118	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HRAS—rectum cancer	6.32e-05	0.000118	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—KRAS—rectum cancer	6.32e-05	0.000118	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—NRAS—rectum cancer	6.28e-05	0.000117	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—NRAS—rectum cancer	6.26e-05	0.000117	CbGpPWpGaD
Regorafenib—FGFR2—Disease—NRAS—rectum cancer	6.22e-05	0.000116	CbGpPWpGaD
Regorafenib—KIT—Disease—NRAS—rectum cancer	6.11e-05	0.000114	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—HRAS—rectum cancer	6.07e-05	0.000113	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HRAS—rectum cancer	6.07e-05	0.000113	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—NRAS—rectum cancer	5.84e-05	0.000109	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—KRAS—rectum cancer	5.8e-05	0.000108	CbGpPWpGaD
Regorafenib—FGFR1—Disease—NRAS—rectum cancer	5.8e-05	0.000108	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—NRAS—rectum cancer	5.78e-05	0.000108	CbGpPWpGaD
Regorafenib—BRAF—Disease—KRAS—rectum cancer	5.78e-05	0.000108	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—TYMS—rectum cancer	5.74e-05	0.000107	CbGpPWpGaD
Regorafenib—KIT—Immune System—KRAS—rectum cancer	5.7e-05	0.000106	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—NRAS—rectum cancer	5.64e-05	0.000105	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NRAS—rectum cancer	5.52e-05	0.000103	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—NRAS—rectum cancer	5.51e-05	0.000103	CbGpPWpGaD
Regorafenib—ABL1—Immune System—NRAS—rectum cancer	5.5e-05	0.000102	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KRAS—rectum cancer	5.41e-05	0.000101	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KRAS—rectum cancer	5.39e-05	0.0001	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HRAS—rectum cancer	5.37e-05	0.0001	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KRAS—rectum cancer	5.36e-05	9.97e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—KRAS—rectum cancer	5.26e-05	9.79e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NRAS—rectum cancer	5.21e-05	9.7e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—NRAS—rectum cancer	5.03e-05	9.37e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KRAS—rectum cancer	5.03e-05	9.36e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KRAS—rectum cancer	4.99e-05	9.3e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KRAS—rectum cancer	4.98e-05	9.27e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HRAS—rectum cancer	4.93e-05	9.18e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—HRAS—rectum cancer	4.91e-05	9.15e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KRAS—rectum cancer	4.86e-05	9.05e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—TYMS—rectum cancer	4.86e-05	9.04e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—HRAS—rectum cancer	4.84e-05	9.02e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KRAS—rectum cancer	4.75e-05	8.85e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NRAS—rectum cancer	4.75e-05	8.84e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—KRAS—rectum cancer	4.74e-05	8.82e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KRAS—rectum cancer	4.73e-05	8.82e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NRAS—rectum cancer	4.7e-05	8.75e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NRAS—rectum cancer	4.64e-05	8.65e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HRAS—rectum cancer	4.6e-05	8.56e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HRAS—rectum cancer	4.58e-05	8.54e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HRAS—rectum cancer	4.55e-05	8.48e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KRAS—rectum cancer	4.49e-05	8.35e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—HRAS—rectum cancer	4.47e-05	8.33e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—rectum cancer	4.47e-05	8.32e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NRAS—rectum cancer	4.36e-05	8.11e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—TYMS—rectum cancer	4.33e-05	8.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—rectum cancer	4.33e-05	8.06e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NRAS—rectum cancer	4.28e-05	7.97e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—rectum cancer	4.27e-05	7.96e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—rectum cancer	4.24e-05	7.9e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—rectum cancer	4.23e-05	7.88e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TYMS—rectum cancer	4.23e-05	7.88e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—rectum cancer	4.22e-05	7.86e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—rectum cancer	4.13e-05	7.69e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—rectum cancer	4.08e-05	7.61e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—rectum cancer	4.06e-05	7.56e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—rectum cancer	4.05e-05	7.54e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—rectum cancer	4.05e-05	7.54e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—rectum cancer	4.04e-05	7.52e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—rectum cancer	4.03e-05	7.5e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—rectum cancer	4.02e-05	7.49e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—rectum cancer	4e-05	7.44e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TYMS—rectum cancer	3.95e-05	7.36e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—rectum cancer	3.81e-05	7.1e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—rectum cancer	3.75e-05	6.98e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—rectum cancer	3.68e-05	6.86e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—rectum cancer	3.68e-05	6.85e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—rectum cancer	3.65e-05	6.8e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—rectum cancer	3.63e-05	6.76e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—rectum cancer	3.6e-05	6.7e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—rectum cancer	3.5e-05	6.51e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—rectum cancer	3.49e-05	6.49e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—rectum cancer	3.47e-05	6.47e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—rectum cancer	3.44e-05	6.4e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—rectum cancer	3.4e-05	6.33e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—rectum cancer	3.33e-05	6.21e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—rectum cancer	3.27e-05	6.1e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—rectum cancer	3.25e-05	6.06e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—rectum cancer	3.19e-05	5.94e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—rectum cancer	3.14e-05	5.85e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—rectum cancer	3.13e-05	5.83e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—rectum cancer	3.11e-05	5.79e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—rectum cancer	3.1e-05	5.77e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—rectum cancer	2.97e-05	5.53e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—rectum cancer	2.96e-05	5.52e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—rectum cancer	2.8e-05	5.21e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—rectum cancer	2.79e-05	5.2e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—rectum cancer	2.67e-05	4.97e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TYMS—rectum cancer	2.61e-05	4.85e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—rectum cancer	2.49e-05	4.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—rectum cancer	2.38e-05	4.43e-05	CbGpPWpGaD
